Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals

被引:449
作者
Leen, Ann M.
Myers, G. Doug
Sili, Uluhan
Huls, M. Helen
Weiss, Heidi
Leung, Kathryn S.
Carrum, George
Krance, Robert A.
Chang, Chung-Che
Molldrem, Jeffrey J.
Gee, Adrian P.
Brenner, Malcolm K.
Heslop, Helen E.
Rooney, Cliona M.
Bollard, Catherine M. [1 ]
机构
[1] Baylor Coll Med, Methodist Hosp, Ctr Cell & Gene Therapy, Houston, TX 77030 USA
[2] Baylor Coll Med, Methodist Hosp, Dept Pediat, Houston, TX 77030 USA
[3] Baylor Coll Med, Methodist Hosp, Dept Immunol, Houston, TX 77030 USA
[4] Baylor Coll Med, Methodist Hosp, Dept Med, Houston, TX 77030 USA
[5] Baylor Coll Med, Methodist Hosp, Dept Virol, Houston, TX 77030 USA
[6] Texas Childrens Hosp, Houston, TX 77030 USA
[7] Cornell Univ, TMHRI, Methodist Hosp, Dept Pathol,Weill Med Coll, Houston, TX 77030 USA
[8] Univ Texas, MD Anderson Canc Ctr, Dept Med, Houston, TX 77030 USA
关键词
D O I
10.1038/nm1475
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Immunocompromised individuals are at high risk for life-threatening diseases, especially those caused by cytomegalovirus (CMV), Epstein-Barr virus (EBV) and adenovirus. Conventional therapeutics are primarily active only against CMV, and resistance is frequent. Adoptive transfer of polyclonal cytotoxic T lymphocytes (CTLs) specific for CMV or EBV seems promising, but it is unclear whether this strategy can be extended to adenovirus, which comprises many serotypes. In addition, the preparation of a specific CTL line for each virus in every eligible individual would be impractical. Here we describe genetic modification of antigen-presenting cell lines to facilitate the production of CD4(+) and CD8(+) T lymphocytes specific for CMV, EBV and several serotypes of adenovirus from a single cell culture. When administered to immunocompromised individuals, the single T lymphocyte line expands into multiple discrete virus-specific populations that supply clinically measurable antiviral activity. Monoculture-derived multispecific CTL infusion could provide a safe and efficient means to restore virus-specific immunity in the immunocompromised host.
引用
收藏
页码:1160 / 1166
页数:7
相关论文
共 32 条
[1]   Cytotoxic T lymphocyte therapy for Epstein-Barr virus Hodgkin's disease [J].
Bollard, CM ;
Aguilar, L ;
Straathof, KC ;
Gahn, B ;
Huls, MH ;
Rousseau, A ;
Sixbey, J ;
Gresik, MV ;
Carrum, G ;
Hudson, M ;
Dilloo, D ;
Gee, A ;
Brenner, MK ;
Rooney, CM ;
Heslop, HE .
JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 200 (12) :1623-1633
[2]   Adoptive immunotherapy for posttransplantation viral infections [J].
Bollard, CM ;
Kuehnle, I ;
Leen, A ;
Rooney, CM ;
Heslop, HE .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2004, 10 (03) :143-155
[3]   Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells [J].
Bunde, T ;
Kirchner, A ;
Hoffmeister, B ;
Habedank, D ;
Hetzer, R ;
Cherepnev, G ;
Proesch, S ;
Reinke, P ;
Volk, HD ;
Lehmkuhl, H ;
Kern, F .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 201 (07) :1031-1036
[4]   SEQUENCE POLYMORPHISM IN THE EPSTEIN-BARR-VIRUS LATENT MEMBRANE-PROTEIN (LMP)-2 GENE [J].
BUSSON, P ;
EDWARDS, RH ;
TURSZ, T ;
RAABTRAUB, N .
JOURNAL OF GENERAL VIROLOGY, 1995, 76 :139-145
[5]   Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery [J].
Chakrabarti, S ;
Mautner, V ;
Osman, H ;
Collingham, KE ;
Fegan, CD ;
Klapper, PE ;
Moss, PAH ;
Milligan, DW .
BLOOD, 2002, 100 (05) :1619-1627
[6]   High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution [J].
Chakrabarti, S ;
Mackinnon, S ;
Chopra, R ;
Kottaridis, PD ;
Peggs, K ;
O'Gorman, P ;
Chakraverty, R ;
Marshall, T ;
Osman, H ;
Mahendra, P ;
Craddock, C ;
Waldmann, H ;
Hale, G ;
Fegan, CD ;
Yong, K ;
Goldstone, AH ;
Linch, DC ;
Milligan, DW .
BLOOD, 2002, 99 (12) :4357-4363
[7]   Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers [J].
Cobbold, M ;
Khan, N ;
Pourgheysari, B ;
Tauro, S ;
McDonald, D ;
Osman, H ;
Assenmacher, M ;
Billingham, L ;
Steward, C ;
Crawley, C ;
Olavarria, E ;
Goldman, J ;
Chakraverty, R ;
Mahendra, P ;
Craddock, C ;
Moss, PAH .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (03) :379-386
[8]   Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy [J].
Einsele, H ;
Roosnek, E ;
Rufer, N ;
Sinzger, C ;
Riegler, S ;
Löffler, J ;
Grigoleit, U ;
Moris, A ;
Rammensee, HG ;
Kanz, L ;
Kleihauer, A ;
Frank, F ;
Jahn, G ;
Hebart, H .
BLOOD, 2002, 99 (11) :3916-3922
[9]   An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs [J].
Gottschalk, S ;
Ng, CYC ;
Perez, M ;
Smith, CA ;
Sample, C ;
Brenner, MK ;
Heslop, HE ;
Rooney, CM .
BLOOD, 2001, 97 (04) :835-843
[10]   Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease:: prophylactic infusion of EBV-specific cytotoxic T cells [J].
Gustafsson, Å ;
Levitsky, V ;
Zou, JZ ;
Frisan, T ;
Dalianis, T ;
Ljungman, P ;
Ringden, O ;
Winiarski, J ;
Ernberg, I ;
Masucci, MG .
BLOOD, 2000, 95 (03) :807-814